Prolynx: Valuation, Funding & Investors
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and other metabolic diseases. The Company is advancing a proprietary portfolio of extended-duration therapeutic candidates, targeting once monthly and once-quarterly dosing, optimized to smooth the peaks and troughs that can contribute to tolerability issues, and to support more consistent, long-term treatment.
Leadership & Board
- Current Number of Employees
- 38
- Current LinkedIn Followers
- 3,063
Latest Estimated Valuation
- Total Amount Raised
- $70M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $70M
- Latest Funding Round
- Series A
Employee Trend
Prolynx had 38 employees as of November 2, 2026. The number of employees increased by 0 (0.00%) week-over-week.
38Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Prolynx had 3,063 followers as of November 2, 2026. The number of followers increased by 8 (0.26%) week-over-week.
3,063Latest Followers Count
8(0.26%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 11, 2025 | Series A | $70.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| OrbiMed | Series A |
| 5AM Ventures | Series A |
| Monograph Capital | Series A |
Similar Companies
A snapshot of private companies similar to Prolynx, helping you discover and navigate related company profiles.
Related News and Analysis
